Skip to main content
. 2018 Oct 25;20(3):381–390. doi: 10.1080/15384047.2018.1529112

Figure 1.

Figure 1.

Montelukast induced cytotoxicity in human MM cell lines. (a) MM cell lines were treated with increasing concentrations of montelukast for 48 hours, or (b) montelukast (25μM) for 12, 24, 36, 48 hours, and the cell viability of MM cell lines were assessed by Beckman-Coulter cell counter. (c) Montelukast inhibited clonogenicity, as determined by colony formation assay. Colonies with diameters ≥0.1 mm were counted. 0 μM: 0.1% DMSO. (d) U266 and RPMI 8226 cells were incubated with montelukast (25μM) for 16 h and MM cells were arrested in the G0/G1 phase, RPMI 8226 was also arrested in the G2/M phase. The cell cycle distribution was determined by flow cytometry analysis of the DNA content. (e) U266 and RPMI 8226 were cultured with increasing doses of montelukast (15–40 μM) for 24 hours or montelukast (25μM) for 6, 12, 24, 36 hours and cell lysates were assessed by western blot for PARP1 and c-Myc. Data are presented as mean ± SD derived from 3 independent experiments. ***P ≤ 0.001 compared with control group. MNK: montelukast. c-PARP1: cleaved PARP1. CTL: control.